Novo Integrated Sciences, Inc. (NVOS)
OTCMKTS · Delayed Price · Currency is USD
0.0200
0.00 (0.00%)
Jun 3, 2026, 4:00 PM EST
Novo Integrated Sciences Revenue
In the fiscal year ending August 31, 2024, Novo Integrated Sciences had annual revenue of $13.29M with 5.75% growth. Novo Integrated Sciences had revenue of $3.08M in the quarter ending August 31, 2024, a decrease of -6.74%.
Revenue
13.29M
Revenue Growth
+5.75%
P/S Ratio
0.03
Revenue / Employee
69.97K
Employees
264
Market Cap
394.61K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 13.29M | 722.34K | 5.75% |
| Aug 31, 2023 | 12.57M | 834.08K | 7.11% |
| Aug 31, 2022 | 11.74M | 2.43M | 26.14% |
| Aug 31, 2021 | 9.31M | 1.44M | 18.38% |
| Aug 31, 2020 | 7.86M | -1.56M | -16.57% |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ModivCare | 2.69B |
| Aesthetic Medical International Holdings Group | 103.35M |
| Veltex | 70.13M |
| Ethema Health | 15.42M |
| Stem Cell Authority | 3.33M |
| CYIOS | 1.49M |
| Dental Patient Care America | 475.52K |
| IMAC Holdings | 22.72K |
Novo Integrated Sciences News
- 1 year ago - Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results - Business Wire
- 2 years ago - Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results - Business Wire
- 2 years ago - Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program - Business Wire
- 2 years ago - Novo Integrated Sciences files to sell 3.5M shares of common stock for holders - TheFly
- 2 years ago - Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program - Business Wire
- 2 years ago - Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million - Business Wire
- 2 years ago - Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products - Business Wire
- 2 years ago - Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note - Business Wire